Alcon reveals final data from Vivity Registry Study

Alcon revealed final data from its Vivity Registry Study, which monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens. Data from more than 900 cataract patients demonstrated sustained clinical performance, high patient satisfaction and reduced dependence upon spectacles. Evidence also suggested that AcrySof IQ Vivity can be used successfully in a broad range of patients, providing surgeons and patients with additional treatment options. The Vivity Registry Study was a multicentre, ambispective, non-comparative, open-label, non-interventional registry study conducted across 41 sites from eight countries: Australia, Belgium, Germany, New Zealand, the Netherlands, Portugal, Spain and the United Kingdom. Researchers concluded that:3 Three-quarters of patients reported no difficulty with their sight for activities in everyday life. Most patients reported they were satisfied with their sight. More than 91% of patients reported no halos, glares or starbursts. Excellent binocular distance and intermediate uncorrected visual acuity was observed, with mean Snellen visual acuity values of 20/20 and 20/25, respectively. More than 78% and 88% of patients reported they no longer needed to use glasses to see at arm’s length and far away, respectively.